top of page
검색

Sandoz launches Enzeevu aflibercept biosimilar in US with new private-label distribution agreement

작성자 사진: nuaxia
nuaxia
1일 전
2분 분량

Sandoz has launched its interchangeable aflibercept biosimilar Enzeevu in the United States and announced a multi-year private-label distribution arrangement, expanding commercial competition in treatments for retinal vascular diseases.


Sandoz announced on 16 November 2026 that it had commercially launched Enzeevu (aflibercept-abzv), an interchangeable biosimilar to Eylea, in the United States as a 2 mg pre-filled syringe for approved ophthalmic indications including neovascular age-related macular degeneration and diabetic macular oedema.


The company also disclosed a multi-year private-label distribution agreement establishing an additional US commercial channel from mid-2027, with committed volumes expected from the second half of that year; Enzeevu originally received FDA approval in August 2024, so the November announcement concerns market launch and distribution rather than a newly granted regulatory approval.

Field

Content

Article Type

Industry Updates

Company

Sandoz

Product Brand Name

Enzeevu

Active Ingredient

Aflibercept-abzv

Product Classification

Interchangeable biosimilar

Reference Product

Eylea

Announcement Date

16 November 2026

Event Type

US commercial product launch and distribution agreement

Commercial Launch Market

United States

Commercial Launch Status

Launched

Original FDA Approval Date

August 2024

New FDA Approval Announced

No

Therapeutic Area

Ophthalmology

Disease Category

Retinal vascular diseases

Indication One

Neovascular age-related macular degeneration

Indication One Abbreviation

nAMD

Indication Two

Diabetic macular oedema

Product Presentation

2 mg pre-filled syringe

Biosimilar Regulatory Status

FDA-approved interchangeable biosimilar

Distribution Agreement Type

Multi-year private-label agreement

Additional Commercial Channel

US private-label distribution

Private-Label Channel Start

Mid-2027

Expected Committed Volumes

From the second half of 2027

Distribution Partner

Not specified in supplied summary

Agreement Financial Terms

Not disclosed in supplied summary

Commercial Strategy

Expand access and distribution of an interchangeable ophthalmic biosimilar

What Happened

Sandoz launched Enzeevu in the US and announced an additional private-label commercial distribution arrangement.

Why It Matters

The launch adds a commercial biosimilar alternative in the US market for widely used retinal disease treatments.

Commercial Significance

Establishes immediate US market presence with a further distribution channel planned for 2027.

Access Significance

Additional biosimilar competition may broaden treatment and purchasing options for retinal disease care.

Regulatory Clarification

The FDA approved Enzeevu in August 2024; November 2026 marks commercial launch rather than a new approval.

Distribution Clarification

The private-label channel is expected to begin in mid-2027, with committed volumes from the second half of that year.

Key Takeaway

Enzeevu is commercially available in the US, with Sandoz planning an additional private-label distribution channel in 2027.

What to Watch

US market uptake, reimbursement, pricing competition, private-label rollout and committed distribution volumes.

Primary Source

Sandoz

Primary Source URL

https://www.sandoz.com/sandoz-launches-enzeevu-us-and-announces-key-private-label-agreement-expanding-treatment-choice/

Submitted Source

EQS News

Submitted Source URL

https://www.eqs-news.com/news/ad-hoc/sandoz-launches-enzeevu-in-the-us-and-announces-key-private-label-agreement-expanding-treatment-choice-for-patients-with-retinal-diseases/c8143ba5-e941-4ff0-b594-c7355a3372fa_en

Relevant Date

16 November 2026


Discover how nuaxia can support your next medical education initiative:

 
 
 

댓글

별점 5점 중 0점을 주었습니다.
등록된 평점 없음

평점 추가
bottom of page